Discovery of long-term toxic exposure among Xerxes workers

The discovery of long-term toxic exposure among workers at Humboldt Chemical’s Xerxes plant transforms a disputed compensation claim into a far-reaching record of occupational illness. Decades of blood measurements, interpreted by a nephrologist and considered alongside clinical histories, show changes consistent with kidney, liver, and bone-marrow dysfunction. The findings do not erase the difficulty of assigning any one worker’s illness to a single cause. They do, however, make the company’s earlier insistence that such a connection could not be proved newly consequential: the evidence had been accumulating in records while the people represented in them remained largely unaware of what was happening to their health.

From solvent to disputed exposure

Xerxine was a chlorinated-hydrocarbon solvent used for cleaning oil from sheet metal, paint, and similar materials. Its manufacture could release vapors harmful to the liver, kidneys, and central nervous system. Humboldt Chemical began making it in the 1950s, when knowledge of those hazards was limited and control of airborne vapors was not careful. The account of the plant’s later response describes a shift in awareness during the 1960s and 1970s, as research increasingly connected industrial pollution with worker health. Xerxes installed air scrubbers and better-sealed pipes, reducing airborne concentrations to federal standards. By the late 1970s, the U.S. Environmental Protection Agency had set a Xerxine standard of fifty parts per million.

That later control did not settle what workers had inhaled earlier. Joey Pankowski and Steve Ferraro had both worked at Humboldt Chemical for years, beginning in 1961 and 1959 respectively. When they became too sick to work, they sought workers’ compensation, believing their illnesses might be job-related. The company’s position rested in part on the fact that their exposure had occurred before Xerxine’s toxicity was known. The difference between what was understood at the time and what later medical evidence could show became central to the dispute.

The records and their scope

The documentary breakthrough comes when Lotty Herschel reports the results of a consultation with Dr. Christophersen, a nephrologist asked to interpret the company’s medical notebooks. Lotty had kept those notebooks locked in Max Loewenthal’s safe at Beth Israel Hospital, rather than leave them accessible to anyone who might get hold of them. Dr. Christophersen’s review was not based only on a general impression of the papers: she followed up with doctors connected to two patients and compared their medical histories with the recorded blood work.

The surviving records included blood histories for Louisa Djiak from 1963 through 1982 and for Ferraro from 1957 through 1982. They also covered approximately five hundred other employees at the Xerxes plant between 1955 and 1982. The measured values included creatinine, blood urea nitrogen, bilirubin, hematocrit, hemoglobin, and white blood count. Taken together, their changes were consistent with the development of renal, liver, and bone-marrow dysfunction. The archive’s span matters: it reaches across decades of work and makes the issue larger than a pair of claimants whose illnesses could be dismissed as isolated cases.

Louisa Djiak and Steve Ferraro

Louisa’s history gives the records a striking chronology. Her blood work indicates noticeable renal damage by 1967 and severe damage by 1969. Yet the diffuse symptoms she experienced—itching, fatigue, and headaches—began around 1979, and she attributed them to the change of life rather than seeking medical attention. She first went to Dr. Daniel Peters in 1984, at her daughter’s insistence. By then he diagnosed chronic renal failure, which had progressed to an acute stage. Other complications meant that Louisa was not a good candidate for a transplant.

Ferraro’s records offered a parallel, though not identical, case. Dr. Christophersen’s summary ended with his death from aplastic anemia in 1983. The medical histories, the doctors’ accounts, and the chemical information were consistent with exposure to Xerxine; they gave the claim a substantial evidentiary basis. They did not, by themselves, resolve every question about individual causation. The earlier lawsuit had turned on precisely that distinction, with Humboldt pointing to Ferraro’s smoking and Pankowski’s heavy drinking, as well as the polluted air of South Chicago, as alternative explanations for illness.

From a failed suit to a wider case

Art Jurshak’s account of the workers’ compensation case explains why the notebooks alter the meaning of the earlier defeat. He had first approached the company and then filed suit when it refused to negotiate. The case moved quickly because both men were gravely ill. Humboldt argued that the claimants’ smoking, drinking, and exposure to the general air pollution of South Chicago made it impossible to isolate Xerxine as the cause. It also argued that the men had worked at the plant before the chemical’s toxicity was known. The suit failed, and an appellate lawyer Jurshak consulted saw no viable basis for appeal.

A later disclosure complicates that history. Jurshak had received a threatening phone call while considering an appeal. The caller did not name the case, but referred generally to the dangers of using the appellate system. Jurshak said he became angry and tried to build an appeal, yet found no legal path forward. The call did not prove who was responsible or establish that the verdict had been affected, but it places the failed effort within a climate in which pursuing the case carried pressure beyond the courtroom.

When V. I. Warshawski examines the medical findings alongside Jurshak’s insurance report to Mariners Rest, she sees a possible financial explanation for the company’s sensitivity to the records. She concludes that the report helped Humboldt conceal the plant’s high illness and mortality rates in order to obtain favorable insurance rates. Her reconstruction is that employees might have been told their coverage excluded certain tests or hospital costs, with bills then passing through a fiduciary before reaching the insurer. This is presented as her likeliest account of how the arrangement could work, not as a complete documentary demonstration of every step.

Consequences and significance

The notebooks change the scale of the question. The original suit concerned two seriously ill former employees; the records point to a much larger population and a long period of possible exposure. The evidence also sharpens the difference between a legal defense and a medical record: smoking, drinking, background pollution, and the standards of knowledge at the time made causation difficult to establish in court, while repeated blood measurements and clinical histories supplied evidence that had not been available in the same form during the earlier case.

Warshawski therefore approaches Frederick Manheim about organizing claims for hundreds of former Xerxes employees, and possibly current workers. She makes clear that doing so would require him to enlarge his small practice, hire staff, and commit years of work while facing better-resourced opponents. Manheim agrees to take on the effort, saying that after the earlier threat he does not think he can live with himself if he now has a chance to pursue the case and declines it merely to preserve a quiet practice. The discovery thus ends not with a final legal judgment, but with a change in what can be investigated and who is prepared to act. Its force lies in the delayed visibility of the harm: records gathered over decades become legible only when someone places them beside workers’ illnesses, medical expertise, and the history of a case the company had already won.